Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 7, Issue 1, 2005, Pages 36-

  Sharma, Ashish ^a   Ramaswamy, Sriram ^b   Dewan, Vijay K ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ARIPIPRAZOLE; ZIPRASIDONE;

ADULT; ANAMNESIS; CASE REPORT; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; LETTER; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM; TARDIVE DYSKINESIA;

EID: 28244433858     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v07n0107     Document Type: Letter

References (7)

1. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481
2. Keck ME, Muller MB, Binder EB, et al. Ziprasidone-related tardive dyskinesia [letter]. Am J Psychiatry 2004;161:175-176
3. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
4. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389
5. Kalwans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 1972;33:235-246
6. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105-111
7. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia [letter]. Can J Psychiatry 2003;48:771-772